| abstract |
Disclosed are compositions and methods relating to or derived from anti-PD-L1 antibodies. Disclosed are fully human antibodies that bind to PD-L1, PD-L1 binding fragments and derivatives of the antibodies, and PD-L1 binding polypeptides comprising the fragments. Furthermore, nucleic acids encoding the antibodies, antibody fragments and derivatives and polypeptides, cells containing the polynucleotides, methods for producing the antibodies, antibody fragments and derivatives and polypeptides, and the antibodies, antibody fragments and derivatives and polypeptides Methods of treatment of, for example, methods of treating or diagnosing a subject suffering from a PD-L1-related disorder or condition, including various inflammatory disorders and various cancers. [Selection figure] None |